Skip to main content

August 2019, Vol 12, Special Issue: Payers' Perspectives In Oncology: ASCO 2019 Highlights

View Additional ASCO 2019 Coverage

Lung Cancer, Oncology
Repotrectinib, an Investigational TKI, Elicits Responses in Patients with Advanced NSCLC and ROS1 Alterations
Wayne Kuznar
Read More
Leukemia, Oncology
Gilteritinib and CX-01 in the Treatment of Patients with Acute Myeloid Leukemia
Phoebe Starr
Read More
In the Literature, Oncology
Long-Term Outcomes Affect Cost-Effectiveness of CAR T-­Cell Therapy for DLBCL
Read More
In the Literature, Oncology
Alpelisib Prolongs Progression-Free Survival in Advanced Breast Cancer with PIK3CA Mutation
Read More
In the Literature, Oncology
New Triple-Drug Regimen for Newly Diagnosed Patients with Multiple Myeloma
Read More
Leukemia, Oncology
Fixed-Duration Targeted Therapy with Venetoclax plus Obinutuzumab New Front-Line Standard for Patients with Chronic Lymphocytic Leukemia
Phoebe Starr
Read More
Biomarkers, Oncology
Larotrectinib Has Wide-Ranging Efficacy in Advanced Solid Tumors with NTRK Gene Fusion
Wayne Kuznar
Read More
Cholangiocarcinoma, Oncology
Expanding Treatment Options for Patients with Advanced Cholangiocarcinoma
Wayne Kuznar
Read More
FDA Approvals
Enfortumab Vedotin Promising Third-Line Option for Metastatic Urothelial Cancer
Phoebe Starr
Read More
FDA Approvals
Selective, Small-Molecule DRD2 Antagonist Induces Tumor Regression in Recurrent High-Grade Glioma
Read More
Page 1 of 3
Results 1 - 10 of 30